tetano
Editor, Senior Moderator
J Clin Virol
. 2020 Aug 4;132:104568.
doi: 10.1016/j.jcv.2020.104568. Online ahead of print.
Unexpected diagnosis of COVID-19-associated disorders by SARS-CoV-2-specific serology
H?l?ne P?r?[SUP] 1 [/SUP], Benoit V?die[SUP] 2 [/SUP], Rapha?l Vernet[SUP] 3 [/SUP], Nathalie Demory[SUP] 4 [/SUP], Najiby Kassis[SUP] 5 [/SUP], Tristan Mirault[SUP] 6 [/SUP], H?l?ne Lazareth[SUP] 7 [/SUP], Geoffroy Volle[SUP] 8 [/SUP], Elsa Denoix[SUP] 8 [/SUP], David Lebeaux[SUP] 9 [/SUP], Isabelle Podglajen[SUP] 10 [/SUP], Laurent B?lec[SUP] 1 [/SUP], David Veyer[SUP] 11 [/SUP]
Affiliations
Abstract
Facing the ongoing pandemic caused by SARS-CoV-2, there is an urgent need for serological assays identifying individuals with on-going infection as well as past coronavirus infectious disease 2019 (COVID-19). We herein evaluated the analytical performances of the CE IVD-labeled Abbott SARS-CoV-2 IgG assay (Des Plaines, IL, USA) carried out with the automated Abbott Architect™ i2000 platform at H?pital Europ?en Georges Pompidou, Paris, France, using serum sample panels obtained from health-workers with COVID-19 history confirmed by positive nucleic acid amplification-based diagnosis and from patients randomly selected for whom serum samples were collected before the COVID-19 epidemic. The Abbott SARS-CoV-2 IgG assay showed sensitivity of 94 % and specificity of 100 %, demonstrating high analytical performances allowing convenient management of suspected on-going and past-infections. In addition, the SARS-CoV-2 IgG positivity rates were compared in COVID-19 positive and COVID-19 free areas from our hospital. Thus, the frequency of SARS-CoV-2-specific IgG was around 10-fold higher in COVID-19 areas than COVID-19 free areas (75 % versus 8%; P < 0.001). Interestingly, several inpatients hospitalized in COVID-19 free areas suffering from a wide range of unexplained clinical features including cardiac, vascular, renal, metabolic and infectious disorders, were unexpectedly found seropositive for SARS-CoV-2 IgG by systematic routine serology, suggesting possible causal involvement of SARS-CoV-2 infection. Taken together, these observations highlight the potential interest of SARS-CoV-2-specific serology in the context of COVID-19 epidemic, especially to assess past SARS-CoV-2 infection as well as possible unexpected COVID-19-associated disorders.
Keywords: Abbott SARS-CoV-2 IgG assay; COVID-19; Diagnosis; SARS-CoV-2; Serology.
. 2020 Aug 4;132:104568.
doi: 10.1016/j.jcv.2020.104568. Online ahead of print.
Unexpected diagnosis of COVID-19-associated disorders by SARS-CoV-2-specific serology
H?l?ne P?r?[SUP] 1 [/SUP], Benoit V?die[SUP] 2 [/SUP], Rapha?l Vernet[SUP] 3 [/SUP], Nathalie Demory[SUP] 4 [/SUP], Najiby Kassis[SUP] 5 [/SUP], Tristan Mirault[SUP] 6 [/SUP], H?l?ne Lazareth[SUP] 7 [/SUP], Geoffroy Volle[SUP] 8 [/SUP], Elsa Denoix[SUP] 8 [/SUP], David Lebeaux[SUP] 9 [/SUP], Isabelle Podglajen[SUP] 10 [/SUP], Laurent B?lec[SUP] 1 [/SUP], David Veyer[SUP] 11 [/SUP]
Affiliations
- PMID: 32890937
- DOI: 10.1016/j.jcv.2020.104568
Abstract
Facing the ongoing pandemic caused by SARS-CoV-2, there is an urgent need for serological assays identifying individuals with on-going infection as well as past coronavirus infectious disease 2019 (COVID-19). We herein evaluated the analytical performances of the CE IVD-labeled Abbott SARS-CoV-2 IgG assay (Des Plaines, IL, USA) carried out with the automated Abbott Architect™ i2000 platform at H?pital Europ?en Georges Pompidou, Paris, France, using serum sample panels obtained from health-workers with COVID-19 history confirmed by positive nucleic acid amplification-based diagnosis and from patients randomly selected for whom serum samples were collected before the COVID-19 epidemic. The Abbott SARS-CoV-2 IgG assay showed sensitivity of 94 % and specificity of 100 %, demonstrating high analytical performances allowing convenient management of suspected on-going and past-infections. In addition, the SARS-CoV-2 IgG positivity rates were compared in COVID-19 positive and COVID-19 free areas from our hospital. Thus, the frequency of SARS-CoV-2-specific IgG was around 10-fold higher in COVID-19 areas than COVID-19 free areas (75 % versus 8%; P < 0.001). Interestingly, several inpatients hospitalized in COVID-19 free areas suffering from a wide range of unexplained clinical features including cardiac, vascular, renal, metabolic and infectious disorders, were unexpectedly found seropositive for SARS-CoV-2 IgG by systematic routine serology, suggesting possible causal involvement of SARS-CoV-2 infection. Taken together, these observations highlight the potential interest of SARS-CoV-2-specific serology in the context of COVID-19 epidemic, especially to assess past SARS-CoV-2 infection as well as possible unexpected COVID-19-associated disorders.
Keywords: Abbott SARS-CoV-2 IgG assay; COVID-19; Diagnosis; SARS-CoV-2; Serology.